Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD

1.3  0 (0%)

Premarket: 1.3 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AKYA. AKYA was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of AKYA have multiple concerns. AKYA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKYA had negative earnings in the past year.
In the past year AKYA has reported a negative cash flow from operations.
In the past 5 years AKYA always reported negative net income.
In the past 5 years AKYA always reported negative operating cash flow.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of AKYA (-44.29%) is worse than 82.14% of its industry peers.
AKYA has a Return On Equity of -728.97%. This is amonst the worse of the industry: AKYA underperforms 92.86% of its industry peers.
Industry RankSector Rank
ROA -44.29%
ROE -728.97%
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

With a decent Gross Margin value of 58.62%, AKYA is doing good in the industry, outperforming 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of AKYA has remained more or less at the same level.
AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKYA has more shares outstanding
AKYA has more shares outstanding than it did 5 years ago.
AKYA has a worse debt/assets ratio than last year.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -2.83. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
AKYA has a worse Altman-Z score (-2.83) than 85.71% of its industry peers.
A Debt/Equity ratio of 10.12 is on the high side and indicates that AKYA has dependencies on debt financing.
AKYA has a Debt to Equity ratio of 10.12. This is amonst the worse of the industry: AKYA underperforms 92.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.12
Debt/FCF N/A
Altman-Z -2.83
ROIC/WACCN/A
WACC12.5%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.61 indicates that AKYA has no problem at all paying its short term obligations.
With a Current ratio value of 2.61, AKYA perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that AKYA should not have too much problems paying its short term obligations.
AKYA has a Quick ratio of 1.78. This is comparable to the rest of the industry: AKYA outperforms 42.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 1.78
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

AKYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.69%, which is quite impressive.
Looking at the last year, AKYA shows a very negative growth in Revenue. The Revenue has decreased by -15.48% in the last year.
Measured over the past years, AKYA shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-15.48%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%

3.2 Future

The Earnings Per Share is expected to grow by 12.72% on average over the next years. This is quite good.
AKYA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.45% yearly.
EPS Next Y42.36%
EPS Next 2Y24.76%
EPS Next 3Y16.59%
EPS Next 5Y12.72%
Revenue Next Year10.12%
Revenue Next 2Y11.91%
Revenue Next 3Y9.62%
Revenue Next 5Y10.45%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKYA. In the last year negative earnings were reported.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as AKYA's earnings are expected to grow with 16.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y16.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (5/22/2025, 7:58:41 PM)

Premarket: 1.3 0 (0%)

1.3

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners34.52%
Inst Owner Change7.93%
Ins Owners4.61%
Ins Owner Change11.98%
Market Cap64.84M
Analysts52.31
Price Target3.05 (134.62%)
Short Float %N/A
Short Ratio10.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.81%
Min EPS beat(2)-2.56%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-16.36%
Min EPS beat(4)-62.97%
Max EPS beat(4)1.15%
EPS beat(8)4
Avg EPS beat(8)-2.1%
EPS beat(12)4
Avg EPS beat(12)-5.89%
EPS beat(16)5
Avg EPS beat(16)-130.7%
Revenue beat(2)0
Avg Revenue beat(2)-14.69%
Min Revenue beat(2)-27.44%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-14.71%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)4
Avg Revenue beat(8)-6.51%
Revenue beat(12)8
Avg Revenue beat(12)-2.64%
Revenue beat(16)10
Avg Revenue beat(16)-1.86%
PT rev (1m)-4.78%
PT rev (3m)-14.57%
EPS NQ rev (1m)-1.23%
EPS NQ rev (3m)-3.14%
EPS NY rev (1m)0.22%
EPS NY rev (3m)-2.58%
Revenue NQ rev (1m)-0.92%
Revenue NQ rev (3m)-0.53%
Revenue NY rev (1m)-1.21%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.79
P/FCF N/A
P/OCF N/A
P/B 8.54
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS1.64
BVpS0.15
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.29%
ROE -728.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.62%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 10.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.09%
Cap/Sales 3.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 1.78
Altman-Z -2.83
F-Score3
WACC12.5%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y42.36%
EPS Next 2Y24.76%
EPS Next 3Y16.59%
EPS Next 5Y12.72%
Revenue 1Y (TTM)-15.48%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%
Revenue Next Year10.12%
Revenue Next 2Y11.91%
Revenue Next 3Y9.62%
Revenue Next 5Y10.45%
EBIT growth 1Y29.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.25%
EBIT Next 3Y20.4%
EBIT Next 5Y16.7%
FCF growth 1Y14.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.35%
OCF growth 3YN/A
OCF growth 5YN/A